Effects of Omeprazole on the Pharmacokinetic Profiles of Lisdexamfetamine Dimesylate and Extended-Release Mixed Amphetamine Salts in Adults

References

• . Kessler RC, Adler L, Barkley R, . The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163(4):716–723
   PubMed Web of Science ®Google Scholar
• . Population Division US Census Bureau. Table 2: Annual Estimates of the Resident Population by Sex and Selected Age Groups for the United States: April 1, 2000 to July 1, 2008 (NC-EST2008-02). June 8, 2009. http://www.census.gov, then search NC-EST2008-02. Accessed August 8, 2009
   Google Scholar
• . Greenfield B, Hechman L. Treatment of attention deficit hyperactivity disorder in adults. Expert Rev Neurother. 2005;5(1):107–121
   PubMedGoogle Scholar
• . National Institute for Health and Clinical Excellence. Attention Deficit Hyperactivity Disorder: Diagnosis and Management of ADHD in Children, Young People, and Adults. NICE Clinical Guideline 72. http://www.nice.org.uk/nicemedia/pdf/ADHDFullGuideline.pdf. Accessed August 8, 2009
   Google Scholar
• . Lamberg L. ADHD often undiagnosed in adults: appropriate treatment may benefit work, family, social life. JAMA. 2003;290(12):1565–1567
   PubMed Web of Science ®Google Scholar
• . Weiss MD, Weiss JR. A guide to the treatment of adults with ADHD. J Clin Psychiatry. 2004;65( suppl 3):27–37
   PubMed Web of Science ®Google Scholar
• . Adler LA, Chua HC. Management of ADHD in adults. J Clin Psychiatry. 2002;63( suppl 12):29–35
   PubMed Web of Science ®Google Scholar
• . Prince JB. Pharmacotherapy of attention-deficit hyperactivity disorder in children and adolescents: update on new stimulant preparations, atomoxetine, and novel treatments. Child Adolesc Psychiatr Clin N Am. 2006;15(1):13–50
   PubMed Web of Science ®Google Scholar
• . Sallee FR, Smirnoff AV. Adderall XR: long acting stimulant for single daily dosing. Expert Rev Neurother. 2004;4(6):927–934
   PubMedGoogle Scholar
• . Focalin XR [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2009
   Google Scholar
• . Ritalin LA [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2007
   Google Scholar
• . Slone Epidemiology Center at Boston University. Patterns of Medication Use in the United States 2006. A Report from the Slone Survey. http://www.bu.edu/slone/SloneSurvey/AnnualRpt/SloneSurveyWebReport2006.pdf. Accessed August 8, 2009
   Google Scholar
• . Prilosec [package insert]. Wilmington, DE: AstraZeneca LP; 2008
   Google Scholar
• . Shi S, Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol. 2008;64(10):935–951
   PubMed Web of Science ®Google Scholar
• . Dent J, El-Serag HB, Wallander M-A, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2005;54(5):710–717
   PubMed Web of Science ®Google Scholar
• . FDA Approves Prilosec OTC to Treat Frequent Heartburn. http://www.fda.gov/bbs/topics/news/2003/new00916.html. Accessed August 8, 2009
   Google Scholar
• . Prilosec OTC [package insert]. Cincinnati, OH: Procter and Gamble; 2009
   Google Scholar
• . Jacobson BC, Ferris TG, Shea TL, Mahlis EM, Lee TH, Wang TC. Who is using chronic acid suppression therapy and why? Am J Gastroenterol. 2003;98(1):51–58
   PubMed Web of Science ®Google Scholar
• . Biederman J, Krishnan S, Zhang Y, McGough JJ, Findling RL. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clin Ther. 2007;29(3):450–463
   PubMed Web of Science ®Google Scholar
• . Pennick M. Hydrolytic conversion of lisdexamfetamine dimesylate to the active moiety, d-amphetamine. Poster presented at: Society of Biological Psychiatry's 64th Annual Scientific Convention and Meeting; May 14–16, 2009; Vancouver, British Columbia, Canada
   Google Scholar
• . Pennick M. Absorption of lisdexamfetamine dimesylate and hydrolysis to form the active moiety, d-amphetamine. Poster presented at: New Clinical Drug Evaluation Unit 49th Annual Meeting; June 29–July 2, 2009; Hollywood, FL
   Google Scholar
• . Adler LA, Goodman DW, Kollins SH, ; 303 Study Group. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2008;69(9):1364–1373
   PubMed Web of Science ®Google Scholar
• . Weisler R, Young J, Mattingly G, Gao J, Squires L, Adler L. Long-term safety and efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. Poster presented at: the US Psychiatric and Mental Health Congress; October 30–November 2, 2008; San Diego, CA. Poster 206
   Google Scholar
• . Shojaei A, Ermer JC, Krishnan S. Lisdexamfetamine dimesylate as a treatment for ADHD: dosage formulation and pH effects. Poster presented at: the 160th Annual Meeting of the American Psychiatric Association; May 19–24, 2007; San Diego, CA. Poster NR 740
   Google Scholar
• . Ermer J, Homolka R, Martin P, Buckwalter M, Purkayastha J, Roesch BG. Linear dose proportionality, low inter- and intrasubject variability, and safety of lisdexamfetamine dimesylate in an open-label single-dose pharmacokinetic study in healthy adult volunteers. Poster presented at: The American College of Clinical Pharmacy's Annual Meeting; October 19–22, 2008; Louisville, KY. Poster 201
   Google Scholar
• . Krishnan S, Zhang Y. Relative bioavailability of lisdexamfetamine 70-mg capsules in fasted and fed healthy adult volunteers and in solution: a single-dose, crossover pharmacokinetic study. J Clin Pharmacol. 2008;48(3):293–302
   PubMed Web of Science ®Google Scholar
• . US Food and Drug Administration. Guidance for Industry: Bioanalytical Method Validation. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070107.pdf. Accessed August 8, 2009
   Google Scholar
• . US Food and Drug Administration. Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products—General Considerations. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidelines/UCM070124.pdf. Accessed August 8, 2009
   Google Scholar
• . Clausen SB, Read SC, Tulloch SJ. Single- and multiple-dose pharmacokinetics of an oral mixed amphetamine salts extended-release formulation in adults. CNS Spectr. 2005;10(12 suppl 20):6–15
   PubMed Web of Science ®Google Scholar
• . Krishnan SM, Stark JG. Multiple daily-dose pharmacokinetics of lisdexamfetamine dimesylate in healthy adult volunteers. Curr Med Res Opin. 2008;24(1):33–40
   PubMed Web of Science ®Google Scholar